IPO - Profile

Summary

We are leading a global transformation toward fully automated microbial quality control within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing.

We are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$20.00 7,900,000 Positive High 46.23%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • PricewaterhouseCoopers LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 14 Jul, 2021

Offer 15 Jul, 2021

Look Ahead

Lock Up Expiry Jan 15, 2022

IPO Terms

Offer Price $20.00
Offer Size 7M

Market Sentiments

Stock Price